Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CD19 cCAR T cells in Refractory ITP
NCT06787989Phase 1Recruiting
- Sponsor
- iCell Gene Therapeutics
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CD19 cCAR-T in immune thrombocytopenia (ITP), sponsored by iCell Gene Therapeutics. Primary endpoint: Number and incidence of adverse events at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
BCMA-CD19 cCAR-T
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06787989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787989.